2022/12/27 更新

写真a

ヤスダ ヨシノリ
安田 康紀
YASUDA Yoshinori
所属
医学部附属病院 糖尿病・内分泌内科 助教
大学院担当
大学院医学系研究科
職名
助教

学位 1

  1. 医学博士 ( 2018年3月   名古屋大学 ) 

研究キーワード 4

  1. 下垂体炎 甲状腺炎 免疫チェックポイント阻害薬

  2. 下垂体炎

  3. 免疫チェックポイント阻害薬

  4. 甲状腺炎

研究分野 3

  1. ライフサイエンス / 内科学一般

  2. ライフサイエンス / 代謝、内分泌学

  3. ライフサイエンス / 免疫学

経歴 1

  1. 名古屋大学   医学部附属病院 糖尿病・内分泌内科   助教

    2021年8月 - 現在

所属学協会 4

  1. 日本糖尿病学会

    2009年11月 - 現在

  2. 日本甲状腺学会

    2009年4月 - 現在

  3. 日本内分泌学会

    2009年4月 - 現在

  4. 日本内科学会

    2008年11月 - 現在

受賞 4

  1. 令和3年度医学系研究科医学奨励賞

    2022年2月   名古屋大学大学院医学系研究科  

     詳細を見る

    受賞国:日本国

  2. ENDO 2020 Outstanding Abstract Award

    2020年6月   Endocrine Society   Primary Thyroid Lymphoma Developing from a Background of Lymphocytic Thyroiditis: First Report in Mice

    Yoshinori Yasuda, MD, PhD, Fabiana Pani, MD, Patrizio Caturegli, MD,MPH.

     詳細を見る

    受賞区分:国際学会・会議・シンポジウム等の賞  受賞国:アメリカ合衆国

  3. 第36回内分泌代謝学サマーセミナー優秀ポスター賞

    2018年8月   日本内分泌学会   抗 PD-1 抗体誘発甲状腺炎マウスモデルの開発と病態の解析

    安田 康紀 , 岩間 信太郎 , 杉山 大介 , 奥地 剛之 , 岡田 則男 , 小林 朋子 , 西川 博嘉 , 有馬 寛

     詳細を見る

    受賞区分:国内学会・会議・シンポジウム等の賞  受賞国:日本国

  4. 第57回日本農村医学会学術総会優秀演題賞 日本農村医学会

    2008年11月   日本農村医学会   発芽玄米食摂取により、糖尿病コントロールが、劇的に改善された2型糖尿病の1例

    安田康紀 , 大河内昌弘 , 本田浩一 , 馬場卓也 , 近藤好博 , 加藤幸正 , 後藤章友 , 神谷泰隆 , 大野恒夫

     詳細を見る

    受賞区分:国内学会・会議・シンポジウム等の賞  受賞国:日本国

 

論文 22

  1. CD4(+) T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice 査読有り 国際誌

    Yasuda Yoshinori, Iwama Shintaro, Sugiyama Daisuke, Okuji Takayuki, Kobayashi Tomoko, Ito Masaaki, Okada Norio, Enomoto Atsushi, Ito Sachiko, Yan Yue, Sugiyama Mariko, Onoue Takeshi, Tsunekawa Taku, Ito Yoshihiro, Takagi Hiroshi, Hagiwara Daisuke, Goto Motomitsu, Suga Hidetaka, Banno Ryoichi, Takahashi Masahide, Nishikawa Hiroyoshi, Arima Hiroshi

    SCIENCE TRANSLATIONAL MEDICINE   13 巻 ( 593 )   2021年5月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Science Translational Medicine  

    Immune-related adverse events induced by anti–programmed cell death–1 antibodies (PD-1-Ab), including destructive thyroiditis (thyroid-irAE), are thought to be caused by activated T cells. However, the T cell subsets that are directly responsible for damaging self-organs remain unclear. To clarify which T cell subsets are involved in the development of thyroid-irAE, a mouse model of thyroid-irAE was analyzed. PD-1-Ab administration 2.5 months after immunization with thyroglobulin caused destructive thyroiditis. Thyroiditis was completely prevented by previous depletion of CD4+ T cells and partially prevented by depleting CD8+ T cells. The frequencies of central and effector memory CD4+ T cell subsets and the secretion of interferon-y after stimulation with thyroglobulin were increased in the cervical lymph nodes of mice with thyroid-irAE compared with controls. Histopathological analysis revealed infiltration of CD4+ T cells expressing granzyme B in thyroid glands and major histocompatibility complex class II expression on thyrocytes in mice with thyroid-irAE. Adoptive transfer of CD4+ T cells from cervical lymph nodes in mice with thyroid-irAE caused destruction of thyroid follicular architecture in the irradiated recipient mice. Flow cytometric analyses showed that the frequencies of central and effector memory CD4+ T cells expressing the cytotoxic marker CD27 were higher in peripheral blood mononuclear cells collected from patients with thyroid-irAE induced by PD-1-Ab versus those without. These data suggest a critical role for cytotoxic memory CD4+ T cells activated by PD-1-Ab in the pathogenesis of thyroid-irAE.

    DOI: 10.1126/scitranslmed.abb7495

    Web of Science

    Scopus

    PubMed

  2. Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors. 査読有り 国際共著 国際誌

    Fabiana Pani , Yoshinori Yasuda , Sylvie T Rousseau , Kevin C Bermea , Solmaz Roshanmehr , Rulin Wang , Srinivasan Yegnasubramanian , Patrizio Caturegli , Luigi Adamo

    Journal for immunotherapy of cancer   10 巻 ( 12 )   2022年12月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1136/jitc-2022-005538

  3. Critical role of rabphilin-3A in the pathophysiology of experimental lymphocytic neurohypophysitis 査読有り 国際誌

    Yasuda Yoshinori, Iwama Shintaro, Kiyota Atsushi, Izumida Hisakazu, Nakashima Kohtaro, Iwata Naoko, Ito Yoshihiro, Morishita Yoshiaki, Goto Motomitsu, Suga Hidetaka, Banno Ryoichi, Enomoto Atsushi, Takahashi Masahide, Arima Hiroshi, Sugimura Yoshihisa

    JOURNAL OF PATHOLOGY   244 巻 ( 4 ) 頁: 469 - 478   2018年4月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Journal of Pathology  

    Autoimmune hypophysitis (AH) is thought to be an autoimmune disease characterized by lymphocytic infiltration of the pituitary gland. Among AH pathologies, lymphocytic infundibulo-neurohypophysitis (LINH) involves infiltration of the neurohypophysis and/or the hypothalamic infundibulum, causing central diabetes insipidus resulting from insufficiency of arginine vasopressin secretion. The pathophysiological and pathogenetic mechanisms underlying LINH are largely unknown. Clinically, differentiating LINH from other pituitary diseases accompanied by mass lesions, including tumours, has often been difficult, because of similar clinical manifestations. We recently reported that rabphilin-3A is an autoantigen and that anti-rabphilin-3A antibodies constitute a possible diagnostic marker for LINH. However, the involvement of rabphilin-3A in the pathogenesis of LINH remains to be elucidated. This study was undertaken to explore the role of rabphilin-3A in lymphocytic neurohypophysitis and to investigate the mechanism. We found that immunization of mice with rabphilin-3A led to neurohypophysitis. Lymphocytic infiltration was observed in the neurohypophysis and supraoptic nucleus 1 month after the first immunization. Mice immunized with rabphilin-3A showed an increase in the volume of urine that was hypotonic as compared with control mice. Administration of a cocktail of monoclonal anti-rabphilin-3A antibodies did not induce neurohypophysitis. However, abatacept, which is a chimeric protein that suppresses T-cell activation, decreased the number of T cells specific for rabphilin-3A in peripheral blood mononuclear cells (PBMCs). It ameliorated lymphocytic infiltration of CD3+ T cells in the neurohypophysis of mice that had been immunized with rabphilin-3A. Additionally, there was a linear association between the number of T cells specific for rabphilin-3A in PBMCs and the number of CD3+ T cells infiltrating the neurohypophysis. In conclusion, we suggest that rabphilin-3A is a pathogenic antigen, and that T cells specific for rabphilin-3A are involved in the pathogenesis of neurohypophysitis in mice. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

    DOI: 10.1002/path.5046

    Web of Science

    Scopus

    PubMed

  4. Resting energy expenditure depends on energy intake during weight loss in people with obesity: a retrospective cohort study. 査読有り

    Tomoko Handa , Takeshi Onoue , Tomoko Kobayashi , Eri Wada , Ayaka Hayase , Tamaki Kinoshita , Ayana Yamagami , Yoshinori Yasuda , Shintaro Iwama , Yohei Kawaguchi , Takashi Miyata , Mariko Sugiyama , Hiroshi Takagi , Daisuke Hagiwara , Hidetaka Suga , Ryoichi Banno , Motomitsu Goto , Hiroshi Arima

    Archives of endocrinology and metabolism     2022年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.20945/2359-3997000000532

  5. Knockdown of endoplasmic reticulum chaperone BiP leads to the death of parvocellular AVP/CRH neurons in mice. 査読有り

    Journal of neuroendocrinology     頁: e13223   2022年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/jne.13223

  6. Mineralocorticoids induce polyuria by reducing apical aquaporin-2 expression of the kidney in partial vasopressin deficiency. 査読有り

    Junki Kurimoto , Hiroshi Takagi , Takashi Miyata , Yohei Kawaguchi , Yuichi Hodai , Tetsuro Tsumura , Daisuke Hagiwara , Tomoko Kobayashi , Yoshinori Yasuda , Mariko Sugiyama , Takeshi Onoue , Shintaro Iwama , Hidetaka Suga , Ryoichi Banno , Takeshi Katsuki , Fumiaki Ando , Shinichi Uchida , Hiroshi Arima

    Endocrine journal     2022年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1507/endocrj.EJ22-0339

  7. Inflammation in VTA Caused by HFD Induces Activation of Dopaminergic Neurons Accompanied by Binge-like Eating. 査読有り

    Runan Sun , Mariko Sugiyama , Sixian Wang , Mitsuhiro Kuno , Tomoyuki Sasaki , Tomonori Hirose , Takashi Miyata , Tomoko Kobayashi , Taku Tsunekawa , Takeshi Onoue , Yoshinori Yasuda , Hiroshi Takagi , Daisuke Hagiwara , Shintaro Iwama , Hidetaka Suga , Hiroshi Arima

    Nutrients   14 巻 ( 18 )   2022年9月

     詳細を見る

    記述言語:英語  

    DOI: 10.3390/nu14183835

  8. The Immune Landscape of Papillary Thyroid Cancer in the Context of Autoimmune Thyroiditis. 招待有り 査読有り 国際共著

    Fabiana Pani , Paola Caria , Yoshinori Yasuda , Miyara Makoto , Stefano Mariotti , Laurence Leenhardt , Solmaz Roshanmehr , Patrizio Caturegli , Camille Buffet

    Cancers   14 巻 ( 17 )   2022年9月

     詳細を見る

    記述言語:英語  

    DOI: 10.3390/cancers14174287

  9. Elevated TSH level, TgAb and prior use of ramucirumab or TKIs as risk factors for thyroid dysfunction in PD-L1 blockade. 査読有り

    Tomoko Kobayashi , Shintaro Iwama , Ayana Yamagami , Yoshinori Yasuda , Takayuki Okuji , Masaaki Ito , Xin Zhou , Masahiko Ando , Takeshi Onoue , Takashi Miyata , Mariko Sugiyama , Daisuke Hagiwara , Hidetaka Suga , Ryoichi Banno , Tetsunari Hase , Masahiro Morise , Takanori Ito , Toyone Kikumori , Megumi Inoue , Yuichi Ando , Norikazu Masuda , Hiroki Kawashima , Naozumi Hashimoto , Hiroshi Arima

    The Journal of clinical endocrinology and metabolism   107 巻 ( 10 )   2022年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1210/clinem/dgac467

  10. Immune checkpoint inhibitor-related thyroid dysfunction 招待有り 査読有り

    Shintaro Iwama , Tomoko Kobayashi , Yoshinori Yasuda , Hiroshi Arima

    Best Practice & Research Clinical Endocrinology & Metabolism     頁: 101660 - 終了ページ101660   2022年4月

     詳細を見る

  11. Functional lactotrophs in induced adenohypophysis differentiated from human iPS cells. 査読有り

    Endocrinology     2022年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  12. Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline. 査読有り

    The Journal of clinical endocrinology and metabolism     2021年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  13. Pre-existing Thyroiditis Ameliorates Papillary Thyroid Cancer: Insights From a New Mouse Model 査読有り 国際誌

    Pani Fabiana, Yasuda Yoshinori, Di Dalmazi Giulia, Chalan Paulina, Gabrielson Kathleen, Adamo Luigi, Sabini Elena, Mariotti Stefano, Caturegli Patrizio

    ENDOCRINOLOGY   162 巻 ( 10 )   2021年10月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Endocrinology (United States)  

    Papillary thyroid cancer (PTC) often co-occurs with Hashimoto's thyroiditis, an association that has long been reported in clinical studies yet remains controversial. Some studies, in fact, have suggested a protective effect of thyroiditis while others have not. We generated a mouse model where PTC and thyroiditis develop in a predictable manner, combining the oncogenic drive of the BRAFv600E mutation (inducible by tamoxifen) to the thyroiditis susceptibility of the NOD.H2h4 strain (inducible by iodine). A total of 113 NOD.H2h4_TPO-CRE-ER_BRAFV600E mice (50 followed throughout lifetime and 63 sacrificed at 16 weeks post tamoxifen) were used to determine whether the PTC phenotype differs when thyroiditis precedes or coincides with the onset of PTC. Mice with pre-existing thyroiditis lived longer (median survival of 28.2 weeks post tamoxifen) than those with concomitant (25.6 weeks) or no (24.5 weeks) thyroiditis (P<0.01 by Laplace regression). PTC developed less frequently (33%) in the pre-existing thyroiditis group than the concomitant (100%) or no (100%) thyroiditis groups (P<0.001 by chi-squared) and showed less aggressive histopathological features. The intratumoral mononuclear cell infiltration was more prominent in mice with pre-existing thyroiditis (P = 0.002 vs the other groups) and sustained by a significant expansion of effector memory CD8 + T cells and CD19 + B cells. These findings shed light on the controversial PTC-thyroiditis association and emphasize the contribution of intratumoral T and B lymphocytes to the evolution of PTC.

    DOI: 10.1210/endocr/bqab144

    Web of Science

    Scopus

    PubMed

  14. Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors 査読有り 国際誌

    Kobayashi T., Iwama S., Sugiyama D., Yasuda Y., Okuji T., Ito M., Ito S., Sugiyama M., Onoue T., Takagi H., Hagiwara D., Ito Y., Suga H., Banno R., Nishikawa H., Arima H.

    Journal for ImmunoTherapy of Cancer   9 巻 ( 5 )   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Journal for ImmunoTherapy of Cancer  

    Background Pituitary dysfunction is a life-threatening immune-related adverse event (irAE) induced by immune checkpoint inhibitors (ICIs). To date, it is not possible to identify patients who may develop pituitary irAEs prior to ICI treatment. The aim of this study was to characterize the predisposition for ICI-induced pituitary irAEs by analyzing anti-pituitary antibodies (APAs) and human leukocyte antigens (HLAs). Methods In this case-control study, APAs and HLA alleles were analyzed in 62 patients (17 who developed ICI-induced isolated adrenocorticotropic hormone deficiency (ICI-IAD), 5 who developed ICI-induced hypophysitis (ICI-H) and 40 who did not develop pituitary irAEs) treated with ICIs between November 2, 2015, and March 31, 2020, at Nagoya University Hospital. The main outcome measures in this study were the association between the development of pituitary irAEs with APAs at baseline and after treatment and HLA alleles. Results Eleven of 17 (64.7%) patients who developed ICI-IAD had APAs at baseline, whereas APAs were positive only in 1 of 40 (2.5%) control patients. Although APAs were negative at baseline in all patients who developed ICI-H, they had become positive before the onset of ICI-H in 3 of 4 patients several weeks after ipilimumab administration. At the onset of ICI-IAD and ICI-H, APAs were positive in 15 of 17 (88.2%) and 4 of 5 (80%) patients, respectively. The prevalence of HLA-Cw12, HLA-DR15, HLA-DQ7, and HLA-DPw9 was significantly higher in patients with ICI-IAD, whereas that of HLA-Cw12 and HLA-DR15 was significantly higher in patients with ICI-H than in controls. Conclusions This study showed distinct and overlapped patterns of APAs and HLA alleles between ICI-IAD and ICI-H. Our findings also showed that positive APAs at baseline and after treatment, together with susceptible HLA alleles, could become predictive biomarkers for ICI-IAD and ICI-H, respectively. Trial registration number UMIN000019024.

    DOI: 10.1136/jitc-2021-002493

    Scopus

    PubMed

  15. Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study 査読有り 国際誌

    Okada Norio, Iwama Shintaro, Okuji Takayuki, Kobayashi Tomoko, Yasuda Yoshinori, Wada Eri, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Hase Tetsunari, Morise Masahiro, Kanda Mitsuro, Yokota Kenji, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Nagino Masato, Kodera Yasuhiro, Fujishiro Mitsuhiro, Hibi Hideharu, Sone Michihiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

    BRITISH JOURNAL OF CANCER   122 巻 ( 6 ) 頁: 771 - 777   2020年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:British Journal of Cancer  

    Background: Anti-programmed cell death-1 (PD-1) antibodies can cause thyroid dysfunction. However, no predictive biomarkers enabling stratification of thyroid dysfunction risk have been identified. Methods: A total of 209 patients treated with an anti-PD-1 antibody were evaluated for anti-thyroid antibodies at baseline and prospectively for thyroid function every 6 weeks for 24 weeks after treatment initiation, and then observed until the visits stopped. Thyroid ultrasonography was performed if the patient was positive for anti-thyroid antibodies at baseline. Results: Of the 209 patients, 19 (9.1%) developed thyroid dysfunction (destructive thyroiditis or hypothyroidism). The cumulative incidence of thyroid dysfunction was significantly higher in patients who were positive vs. negative for anti-thyroid antibodies (15/44 [34.1%] vs. 4/165 [2.4%], p < 0.001). Forty-two patients positive for anti-thyroid antibodies at baseline were divided into two groups according to the presence of an irregular echo pattern. The cumulative incidence of thyroid dysfunction was significantly higher in those with an irregular vs. a regular echo pattern (13/23 [56.5%] vs. 1/19 [5.3%], p = 0.001). None of the patients developed thyroid dysfunction after the initial 24-week period. Conclusions: The risk of thyroid dysfunction induced by anti-PD-1 antibodies can be predicted by evaluation of anti-thyroid antibodies and the thyroid echo pattern at baseline. Trial registration: UMIN000019024.

    DOI: 10.1038/s41416-020-0736-7

    Web of Science

    Scopus

    PubMed

  16. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study 査読有り 国際誌

    Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Okuji Takayuki, Ito Masaaki, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Hibi Hideharu, Sone Michihiko, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

    JOURNAL FOR IMMUNOTHERAPY OF CANCER   8 巻 ( 2 )   2020年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Journal for ImmunoTherapy of Cancer  

    Background Several immune-related adverse events (irAEs) are reported to be associated with therapeutic efficacy of immune checkpoint inhibitors, yet whether pituitary dysfunction, a life-threatening irAE, affects overall survival (OS) in patients with malignancies is unclear. This prospective study examined the association of pituitary dysfunction (pituitary-irAE) with OS of patients with non-small cell lung carcinoma (NSCLC) or malignant melanoma (MM). Methods A total of 174 patients (NSCLC, 108; MM, 66) treated with ipilimumab, nivolumab, pembrolizumab, or atezolizumab at Nagoya University Hospital were evaluated for OS and the development of pituitary-irAE. Kaplan-Meier curves of OS as a function of the development of pituitary-irAE were produced with the log-rank test as a primary endpoint. Results Pituitary-irAE was observed in 16 patients (4 (3.7%) with NSCLC, 12 (18.2%) with MM) having two different disease types: hypophysitis with deficiency of multiple anterior pituitary hormones accompanied by pituitary enlargement, and isolated adrenocorticotropic hormone (ACTH) deficiency without pituitary enlargement. Among these patients, 6 developed pituitary-irAE while being treated with ipilimumab (6/25 patients (24.0%) treated with ipilimumab) and 10 developed pituitary-irAE during treatment with nivolumab or pembrolizumab (10/167 (6.0%)). All 16 patients had ACTH deficiency and were treated with physiological doses of hydrocortisone. The development of pituitary-irAE was associated with better OS in patients with NSCLC (not reached vs 441 (95% CI not calculated) days, p<0.05) and MM (885 (95% CI 434 to 1336) vs 298 (95% CI 84 to 512) days, p<0.05). Conclusions In our study cohort, the incidence of pituitary-irAE was higher than previously reported and the development of pituitary-irAE predicted better prognosis for both NSCLC and MM when patients were treated with physiological doses of hydrocortisone. Clinical trials registration UMIN000019024.

    DOI: 10.1136/jitc-2020-000779

    Web of Science

    Scopus

    PubMed

  17. Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis 査読有り 国際誌

    Yasuda Yoshinori, Iwama Shintaro, Arima Hiroshi

    Endocrine Journal   66 巻 ( 3 ) 頁: 271 - 275   2019年

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:一般社団法人 日本内分泌学会  

    <p>Primary sclerosing cholangitis (PSC) has been known as a cause of secondary osteoporosis, which often requires medication. Herein, we give the first report of a case of a 38-year-old man with fatigue and paralysis in both upper limbs who had been treated with denosumab for secondary osteoporosis associated with PSC. Since bisphosphonate (alendronate) was ineffective in our patient, the treatment was changed from alendronate to denosumab. Despite replacements with calcium and active vitamin D (alfacalcidol; 1-hydroxycholecalciferol), he developed severe hypocalcemia (albumin-adjusted serum calcium: 5.2 mg/dL) 2 weeks after the second administration of denosumab, which required immediate correction. After that, the corrected serum calcium levels were controlled within the normal range with 0.75 μg of eldecalcitol (1α,25-dihydroxy-2β-(3-hydroxypropyloxy)vitamin D3) and increased doses of calcium (1,500 mg daily) and phosphate (900 mg daily) without denosumab. Even though denosumab treatment had been terminated, the T score of the lumbar spine improved from –4.4 to –2.6 by 1 year after the second administration, possibly due to the amelioration of osteomalacia through the treatment with eldecalcitol and the higher doses of calcium and phosphate. This report indicates that denosumab can cause severe hypocalcemia in patients with osteoporosis associated with chronic diseases of the hepatobiliary system including PSC, in turn suggesting that the possibility of vitamin D deficiency or osteomalacia should be considered before administering treatments and that serum calcium levels should be closely monitored to detect life-threatening hypocalcemia in patients who have high risk factors for hypocalcemia.</p>

    DOI: 10.1507/endocrj.EJ18-0545

    Web of Science

    Scopus

    PubMed

  18. Cullin-associated NEDD8-dissociated protein 1, a novel interactor of rabphilin-3A, deubiquitylates rabphilin-3A and regulates arginine vasopressin secretion in PC12 cells. 査読有り

    Kohtaro Nakashima , Seiji Takeuchi , Shintaro Iwama , Atsushi Kiyota , Yoshinori Yasuda , Naoko Iwata , Atsushi Enomoto , Hiroshi Arima , Yoshihisa Sugimura

    Endocrine journal   65 巻 ( 3 ) 頁: 325 - 334   2018年3月

     詳細を見る

    記述言語:英語  

  19. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study 査読有り 国際誌

    Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Tsunekawa Taku, Onoue Takeshi, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Morishita Yoshiaki, Goto Motomitsu, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

    JOURNAL OF THE ENDOCRINE SOCIETY   2 巻 ( 3 ) 頁: 241 - 251   2018年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Journal of the Endocrine Society  

    Context: Immune checkpoint inhibitors, including anti-programmed cell death-1 (PD-1) antibodies, have become promising treatments for a variety of advanced malignancies. However, these medicines can cause immune-related adverse events (irAEs), including endocrinopathies. Objective: This study examined the incidence of endocrine irAEs induced by nivolumab. Patients and Main Outcome Measured: Sixty-six patients treated with nivolumab at Nagoya University Hospital were prospectively evaluated for pituitary hormones, thyroid function, antithyroid antibodies (Abs), and glucose levels every 6 weeks after the initiation of nivolumab for 24 weeks. Results: Four out of 66 patients developed destructive thyroiditis, and three patients developed hypothyroidism requiring levothyroxine replacement. The prevalence of positive anti-thyroglobulin Abs (TgAbs) and/or anti-thyroid peroxidaseAbs (TPOAbs) at baselinewas significantly higher in the group that developed destructive thyroiditis (3/4) compared with the group that did not develop thyroiditis (3/62; P = 0.002). There were no significant differences in other clinical variables between the groups. There were no endocrine irAEs other than destructive thyroiditis during the 24 weeks. The prevalence of TgAbs and/or TPOAbs at baseline was not associated with the development of other irAEs, including pneumonitis, colitis, or skin reactions. Conclusions: Our real-world data showed that destructive thyroiditis was an endocrine irAE that was frequently induced by nivolumab and was significantly associated with positive TgAbs and/or TPOAbs before treatment. Our findings indicate that evaluating these Abs before treatment may help identify patients with a high risk of thyroidal irAEs and may have important clinical benefit.

    DOI: 10.1210/js.2017-00432

    Web of Science

    Scopus

    PubMed

  20. Anti-pituitary antibodies against corticotrophs in IgG4-related hypophysitis 査読有り 国際誌

    Iwata Naoko, Iwama Shintaro, Sugimura Yoshihisa, Yasuda Yoshinori, Nakashima Kohtaro, Takeuchi Seiji, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Goto Motomitsu, Banno Ryoichi, Caturegli Patrizio, Koike Teruhiko, Oshida Yoshiharu, Arima Hiroshi

    PITUITARY   20 巻 ( 3 ) 頁: 301 - 310   2017年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Pituitary  

    Purpose: IgG4-related disease is a systemic inflammatory disease characterized by infiltration of IgG4-positive plasma cells into multiple organs, including the pituitary gland. Autoimmunity is thought to be involved in the pathogenesis of IgG4-related disease. The diagnosis of IgG4-related hypophysitis (IgG4-RH) is difficult because its clinical features, such as pituitary swelling and hypopituitarism, are similar to those of other pituitary diseases, including lymphocytic hypophysitis and sellar/suprasellar tumors. The presence and significance of anti-pituitary antibodies (APA) in IgG4-RH is unclear. Methods: In this case-control study, we used single indirect immunofluorescence on human pituitary substrates to assess the prevalence of serum APA in 17 patients with IgG4-RH, 8 control patients with other pituitary diseases (lymphocytic infundibulo-neurohypophysitis, 3; craniopharyngioma, 2; germinoma, 3), and 9 healthy subjects. We further analyzed the endocrine cells targeted by the antibodies using double indirect immunofluorescence. Results: APA were found in 5 of 17 patients with IgG4-RH (29%), and in none of the pituitary controls or healthy subjects. The endocrine cells targeted by the antibodies in the 5 IgG4-RH cases were exclusively corticotrophs. Antibodies were of the IgG1 subclass, rather than IgG4, in all 5 cases, suggesting that IgG4 is not directly involved in the pathogenesis. Finally, antibodies recognized pro-opiomelanocortin in 2 of the cases. Conclusions: Our study suggests that autoimmunity is involved in the pathogenesis of IgG4-RH and that corticotrophs are the main antigenic target, highlighting a possible new diagnostic marker for this condition.

    DOI: 10.1007/s11102-016-0780-8

    Web of Science

    Scopus

    PubMed

  21. Effect of human leukocyte antigen class II genes on insulin deficiency in slow-onset type 1 diabetes in the Japanese population. 査読有り 国際誌

    Katahira M, Hanakita M, Yasuda Y, Maeda H, Ito T, Segawa S

    Diabetes research and clinical practice   93 巻 ( 1 ) 頁: e33 - 6   2011年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.diabres.2011.03.025

    PubMed

  22. Effect of human leukocyte antigen class II genes on acute-onset and slow-onset type 1 diabetes in the Japanese population. 査読有り 国際誌

    Katahira M, Segawa S, Maeda H, Yasuda Y

    Human immunology   71 巻 ( 8 ) 頁: 789 - 94   2010年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.humimm.2010.05.020

    PubMed

▼全件表示

MISC 7

  1. MMIで全身性多形滲出性紅斑を認め甲状腺全摘したBasedow病の一例

    丹羽 靖浩, 安田 康紀, 加藤 二郎, 篠田 純治  

    日本内分泌学会雑誌88 巻 ( 3 ) 頁: 1019 - 1019   2012年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内分泌学会  

  2. DPP-4阻害薬の併用効果に関する検討

    片平 正人, 瀬川 聡子, 伊藤 竜男, 安田 康紀, 花北 みずき  

    日本内分泌学会雑誌88 巻 ( 1 ) 頁: 329 - 329   2012年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内分泌学会  

  3. 改善傾向にあった急性膵炎に併発した劇症1型糖尿病の1例

    安田 康紀, 片平 正人, 瀬川 聡子, 伊藤 竜男, 花北 みずき  

    糖尿病55 巻 ( 3 ) 頁: 221 - 221   2012年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本糖尿病学会  

  4. 低血糖と偽性アルドステロン症を併発した1例

    花北 みずき, 片平 正人, 瀬川 聡子, 伊藤 竜男, 安田 康紀  

    日本内分泌学会雑誌87 巻 ( 3 ) 頁: 1000 - 1000   2011年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内分泌学会  

  5. 疾患抵抗性ハプロタイプの組み合わせで発症した緩徐進行型1型糖尿病の一例

    伊藤 竜男, 片平 正人, 瀬川 聡子, 前田 晴美, 安田 康紀  

    糖尿病54 巻 ( 5 ) 頁: 388 - 388   2011年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本糖尿病学会  

  6. 発症より1年9ヵ月後、抗IA-2抗体が陰性化し抗GAD抗体は陽性化した1型糖尿病の一例

    瀬川 聡子, 片平 正人, 前田 晴美, 安田 康紀  

    糖尿病53 巻 ( 7 ) 頁: 501 - 504   2010年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本糖尿病学会  

    症例は35歳、女性。初診の3年前の健康診断では異常を指摘されなかった。初診の1ヵ月前より口渇、体重減少が出現し、同3日前に他院で高血糖を指摘され、2005年10月に当科紹介となった。初診時空腹時血糖213mg/dl、HbA1c11.1%、尿中ケトン体陽性を認め、1型糖尿病を疑い即日入院となり、インスリン治療を開始した。血清学的に抗GAD抗体は陰性、抗IA-2抗体は1.9U/mlと陽性所見を認め、尿中CPRは感度以下で、1型糖尿病と診断した。退院後、外来経過観察中にインスリン(insulin aspart Mix30)1日投与量は8単位まで減量でき、血糖コントロールは良好であった。しかし2007年1月、血糖コントロールが再び悪化し、その際に抗IA-2抗体は陰性化、抗GAD抗体は12.3U/mlと陽性化を認め、食後2時間CPRは0.51ng/mlと著明に低下していた。HLA typingではDR4、DR13を有していた。本例は、インスリン依存状態への移行と、膵島自己抗体の変化を観察しえた貴重な一例と考えられた。(著者抄録)

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2010&ichushi_jid=J00926&link_issn=&doc_id=20100820460006&doc_link_id=10.11213%2Ftonyobyo.53.501&url=https%3A%2F%2Fdoi.org%2F10.11213%2Ftonyobyo.53.501&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_2.gif

  7. 急性発症および緩徐進行性1型糖尿病におけるHLA class IIの検討

    片平 正人, 瀬川 聡子, 前田 晴美, 安田 康紀  

    糖尿病53 巻 ( Suppl.1 ) 頁: S - 121   2010年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本糖尿病学会  

▼全件表示

講演・口頭発表等 4

  1. 細胞傷害性CD4陽性T細胞は抗PD-1抗体誘発破壊性甲状腺炎の発症に関与する

    安田 康紀

    第39回内分泌代謝学サマーセミナー   2021年7月9日  日本内分泌学会

     詳細を見る

    開催年月日: 2021年7月

    記述言語:日本語   会議種別:ポスター発表  

    国名:日本国  

  2. 抗PD-1抗体誘発甲状腺炎マウスモデルにおける抗サイログロブリン抗体の役割

    安田 康紀

    第94回日本内分泌学会学術総会  2021年4月22日  日本内分泌学会

     詳細を見る

    開催年月日: 2021年4月

    記述言語:日本語   会議種別:口頭発表(一般)  

    国名:日本国  

  3. 高血糖と肺癌の寄与率が約50%ずつであった高CEA血症を伴った糖尿病の1例

    安田康紀, 篠田純治, 加藤二郎, 丹羽靖浩

    第86回日本糖尿病学会中部地方会  2012年10月13日 

     詳細を見る

    会議種別:口頭発表(一般)  

  4. 改善傾向にあった急性膵炎に併発した劇症1型糖尿病の1例

    安田康紀, 片平正人, 瀬川聡子, 伊藤竜男, 花北みずき

    第84回日本糖尿病学会中部地方会  2011年10月22日 

     詳細を見る

    会議種別:口頭発表(一般)  

科研費 1

  1. 抗PD-1抗体による甲状腺での免疫関連有害事象の非再発機序の解明

    研究課題/研究課題番号:21K20899  2021年8月 - 現在

    日本学術振興会  科学研究費助成事業  研究活動スタート支援

    安田 康紀

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2730000円 ( 直接経費:2100000円 、 間接経費:630000円 )

 

担当経験のある科目 (本学) 4

  1. 分子病態学

    2022

  2. PBL

    2022

  3. 臨床臓器別講義(内分泌・代謝)

    2022

  4. 臨床実習Ⅰ

    2021

     詳細を見る

    経験した症例のレポートを作成し、経過や考察について講義や質疑を行う。

 

メディア報道 1

  1. 抗PD-1抗体による甲状腺副作用の発症メカニズムをマウスで明らかに-名大 インターネットメディア

    QLifePro医療ニュース  2021年5月

     詳細を見る

    執筆者:本人以外